Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06120881 · ClinicalTrials.gov registry record · Early Phase 1
Precision Dosing of Metformin in Youth With T2D
A Early Phase 1 study of Type 2 Diabetes, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT06120881 is a Early Phase 1 study of Type 2 Diabetes that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 20 participants, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06120881, a Early Phase 1 study of Type 2 Diabetes, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study to compare the typically prescribed dose of metformin (1000mg twice a day) with a higher dose of metformin (1350mg twice a day).
Conditions Studied
Interventions
- DRUG Metformin
Study Locations (2)
California
- UCSF Benioff Children's Hospital Oakland, Pediatric Diabetes Clinic - Oakland
- UCSF Benioff Children's Hospital San Francisco, Madison Clinic for Pediatric Diabetes - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-04-25 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06120881
The ClinicalTrials.gov registry entry for NCT06120881 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Metformin is the first listed.
NCT06120881 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06120881 about?
NCT06120881 is a clinical study titled "Precision Dosing of Metformin in Youth With T2D". The purpose of this study to compare the typically prescribed dose of metformin (1000mg twice a day) with a higher dose of metformin (1350mg twice a day).
What is the current status of trial NCT06120881?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2024-04-25. Estimated completion is 2026-12-31.
What conditions does trial NCT06120881 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT06120881?
The interventions under investigation include: Metformin (DRUG).
Who is sponsoring clinical trial NCT06120881?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06120881 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
-
SGLT2i, Hepatic Glucose Production, and SNS
RECRUITING · Early Phase 1
-
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
RECRUITING · Early Phase 1
-
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
RECRUITING · Early Phase 1
-
Antioxidant Treatment of Type 2 Diabetes
COMPLETED · Early Phase 1
-
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.